Pain neuroscience education for adults with chronic musculoskeletal pain: a mixed-methods systematic review and meta-analysis

Key points

1. 01Pain neuroscience education aims to help people reconceptualize their pain as less threatening, rather than directly treating tissue.
2. 02Effects on pain and disability were small and below the 10% threshold for clinical importance (low quality evidence).
3. 03Effects on kinesiophobia (short term) and pain catastrophizing (medium term) were clinically meaningful, suggesting PNE shifts how threatening pain feels.
4. 04Larger benefits appeared when PNE was combined with another intervention rather than delivered alone.
5. 05Qualitative findings stressed letting patients tell their own story and using skilled educators to support pain reconceptualization.

How it was conducted

Design

Mixed-methods systematic review and meta-analysis (segregated quantitative and qualitative synthesis), JBI methodology

Search

13 databases plus registries and theses, 2002 to June 2018; 12 RCTs (quantitative) and 4 qualitative studies

Participants

755 adults with chronic musculoskeletal pain across 12 RCTs (most chronic low back pain), plus 50 in qualitative studies

Intervention

Pain neuroscience education vs control or usual care, including concomitant and head-to-head comparisons

Outcomes

Pain and disability (primary); pain catastrophizing and kinesiophobia (secondary), all converted to a 0 to 100 scale

Analysis

Random effects meta-analysis (pooling only when 5 or more studies), GRADE certainty, ConQual for qualitative

What they found

• Short-term pain: -5.91 on 100mm VAS (95% CI -13.75 to 1.93), not significant, low quality, I-squared 85%.
• Short-term disability: -4.09/100 (95% CI -7.72 to -0.45); medium-term disability: -8.14/100 (95% CI -15.60 to -0.68); both below the 10% clinical threshold.
• Kinesiophobia (short term): -13.55/100 (95% CI -25.89 to -1.21), clinically relevant, moderate certainty (7 RCTs, 372 participants).
• Pain catastrophizing (medium term): -5.26/52 (95% CI -10.59 to 0.08), around the clinically meaningful 10% mark.
• 7 of 12 RCTs scored 5 or higher out of 7 on critical appraisal.

Limitations

• Substantial between-study heterogeneity in design, participants, outcomes, delivery and comparators (pain I-squared 85%).
• Only English-language studies were eligible, so non-English data may have been missed.
• Change SDs had to be estimated for several trials due to incomplete reporting.
• Few qualitative studies, three of which came from the review team, and economic outcomes were not assessed.

Why it matters

For patients

Learning how pain works probably will not greatly reduce your pain on its own, but it can ease fear of movement and catastrophic thinking, especially alongside other treatment.

For clinicians

Use pain neuroscience education as an adjunct to target fear and catastrophizing, not as a standalone fix for pain and disability.

For readers

PNE's main measurable benefit is psychosocial (reduced fear and catastrophizing), with little direct effect on pain or disability.